<p>在过去的 7 天里，美国市场保持平稳，尽管过去一年上涨了 29%，预计收益将以每年 16% 的速度增长。在这种稳定增长的背景下，识别高增长的科技股需要寻找那些展现出强大创新能力和适应能力的公司，以利用这些积极的市场条件。</p>
<h3>美国十大高增长科技公司</h3>
<table>
<thead>
<tr>
<th>名称</th>
<th>收入增长</th>
<th>盈利增长</th>
<th>增长评级</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marker Therapeutics</td>
<td>61.33%</td>
<td>65.71%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Palantir Technologies</td>
<td>27.37%</td>
<td>30.93%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Reddit</td>
<td>21.66%</td>
<td>27.62%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Fabrinet</td>
<td>20.36%</td>
<td>22.11%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Sandisk</td>
<td>35.48%</td>
<td>49.66%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Tenaya Therapeutics</td>
<td>58.52%</td>
<td>60.10%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Zscaler</td>
<td>15.95%</td>
<td>49.84%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Circle Internet Group</td>
<td>20.27%</td>
<td>46.38%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Duos Technologies Group</td>
<td>36.60%</td>
<td>141.19%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>KVH Industries</td>
<td>25.44%</td>
<td>135.75%</td>
<td>★★★★★☆</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们美国高增长科技和人工智能股票筛选器中的 66 只股票的完整列表。</p>
<p>以下是筛选器中一些选择的预览。</p>
<h2>AvePoint (AVPT)</h2>
<p><strong>Simply Wall St 增长评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> AvePoint, Inc. 提供云原生数据管理软件平台，覆盖北美、欧洲、中东、非洲和亚太地区，市值约为 21.6 亿美元。</p>
<p><strong>运营：</strong> 该公司主要通过其软件和编程部门产生收入，总额为 4.195 亿美元。</p>
<p>AvePoint 最近的轨迹展示了其对不断变化的科技环境的强大适应能力，财务表现显著好转。2025 年，该公司的收入从前一年的 3.3048 亿美元增加到 4.195 亿美元，同时净收入从 2909 万美元的净亏损转为 3480 万美元的净收入，反映出每年 32.07% 的盈利增长。这些数据得益于 AvePoint 在多个云平台（如 Microsoft 365 和 Google Cloud）上战略性增强的人工智能治理能力，解决了企业当前面临的关键多云合规和数据安全挑战。这一战略转变不仅提升了他们的服务产品，还使他们在云治理和数据管理的高增长领域中占据了良好位置，抓住了对集成 AI 解决方案日益增长的需求，这些解决方案确保了运营效率和严格的安全协议。</p>
<ul>
<li>点击这里深入了解 AvePoint 的完整分析健康报告。</li>
<li>通过我们的历史报告获取 AvePoint 的过去趋势和表现的见解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/757b1f34-6adb-40bf-9718-ec65d6ce15ee/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/757b1f34-6adb-40bf-9718-ec65d6ce15ee/chart/earnings-and-revenue-growth"/></p>
<p>截至 2026 年 4 月的 AVPT 收益和收入增长</p>
<h2>Krystal Biotech (KRYS)</h2>
<p><strong>Simply Wall St 增长评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Krystal Biotech, Inc. 是一家商业阶段的生物技术公司，专注于发现、开发、制造和商业化针对美国高未满足医疗需求疾病的基因药物，市值为 79.2 亿美元。</p>
<p><strong>运营：</strong> Krystal Biotech 主要通过其基因药物部门产生收入，金额为 3.8913 亿美元。该公司在生物技术领域运营，专注于解决美国重大未满足需求的疾病。</p>
<p>Krystal Biotech 在生物技术领域脱颖而出，过去一年展现出 129.7% 的显著盈利增长，远超行业平均水平 50.1%。这一增长得益于强劲的收入和盈利预测，预计年增长分别为 19.8% 和 22%，超出更广泛市场的预期。该公司对创新的承诺在其最近获得 FDA RMAT 认证的 KB707 中得以体现，旨在治疗晚期非小细胞肺癌，这证明了其在通过先进基因疗法解决关键未满足医疗需求方面的潜力。这一战略重点不仅突显了 Krystal 在开创新疗法中的作用，还使其在一个快速扩张的竞争领域中占据了有利位置。</p>
<ul>
<li>点击这里深入了解 Krystal Biotech 的复杂健康报告。</li>
<li>查看我们的历史表现报告，以获取 Krystal Biotech 过去表现的见解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0bee3c6e-0bb9-45f2-94da-e22eb8705c98/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0bee3c6e-0bb9-45f2-94da-e22eb8705c98/chart/earnings-and-revenue-growth"/></p>
<p>截至 2026 年 4 月的 KRYS 收益和收入增长</p>
<h2>Q2 Holdings (QTWO)</h2>
<p><strong>Simply Wall St 增长评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Q2 Holdings, Inc. 提供针对金融机构、金融科技公司和替代金融公司的数字解决方案，市值为 30.3 亿美元。</p>
<p><strong>运营：</strong> Q2 Holdings 主要通过销售、实施和支持其数字解决方案产生收入，总额为 7.9481 亿美元。该公司为美国的金融机构和金融科技公司提供技术驱动的服务。</p>
<p>Q2 Holdings 在科技行业中脱颖而出，专注于为金融服务提供基于人工智能的解决方案，最近推出的用户活动监控和限制权限模式便是其增强防欺诈保护的有力证明。这些创新是 Q2 更广泛战略的一部分，旨在将人工智能无缝整合到数字银行业务中，反映出向更动态、实时的欺诈缓解技术的显著转变。在财务方面，Q2 展现出强劲的增长，年收益增长 34.5%，年收入增长 9.6%。这一表现得益于诸如第二季度代码等战略举措，该举措通过利用生成性人工智能加速金融机构的开发周期，从而提升平台在竞争市场中的实用性和吸引力。</p>
<ul>
<li>在这里深入了解 Q2 Holdings 的详细健康报告。</li>
<li>通过我们的详细历史业绩报告评估 Q2 Holdings 的过去表现。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/7cb340fc-3efd-4236-8da6-fed86e0ccf86/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/7cb340fc-3efd-4236-8da6-fed86e0ccf86/chart/earnings-and-revenue-growth"/></p>
<p>截至 2026 年 4 月的 QTWO 收益和收入增长</p>
<h2>让它发生</h2>
<ul>
<li>在这里探索我们完整的 66 家美国高增长科技和人工智能股票阵容。</li>
<li>投资了这些股票吗？通过 Simply Wall St 简化您的投资组合管理，并通过我们的警报及时获取股票的关键更新。</li>
<li>通过 Simply Wall St 的免费应用程序发现投资机会的世界，获取各市场无与伦比的股票分析。</li>
</ul>
<h2>准备探索其他投资风格吗？</h2>
<ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>用显示强劲增长潜力的公司充实您的投资组合，分析师和管理层均持乐观态度。</li>
<li>寻找现金流潜力良好但交易价格低于其公允价值的公司。</li>
</ul>
<p><em>本文由 Simply Wall St 撰写，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，采用无偏见的方法，我们的文章并不构成财务建议。</strong> 这并不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们旨在为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均没有持仓。</em></p>
<h3>估值复杂，但我们在这里为您简化。</h3>
<p>通过我们的详细分析，发现 Q2 Holdings 是否可能被低估或高估，分析内容包括 <strong>公允价值估算、潜在风险、股息、内部交易和财务状况。</strong></p>
<p>获取免费分析</p>

KRYS

PLTR

AVPT

<p>美国市场在过去一年中增长了 29%，预计年收益将增长 16%。主要的高增长科技股票包括 Marker Therapeutics、Palantir Technologies 和 Krystal Biotech，显示出显著的收入和收益增长。AvePoint、Krystal Biotech 和 Q2 Holdings 因其创新的方法和强劲的财务表现而受到关注，每家公司都在适应市场需求，专注于人工智能和数字解决方案。整体趋势表明，美国的科技投资环境强劲</p>

<p>Over the last 7 days, the United States market has remained flat, although it is up 29% over the past year with earnings forecast to grow by 16% annually. In this context of steady growth, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on these positive market conditions.</p>
<div class="lb-trans"><p>在过去的 7 天里，美国市场保持平稳，尽管过去一年上涨了 29%，预计收益将以每年 16% 的速度增长。在这种稳定增长的背景下，识别高增长的科技股需要寻找那些展现出强大创新能力和适应能力的公司，以利用这些积极的市场条件。</p>
</div><h3>Top 10 High Growth Tech Companies In The United States</h3>
<div class="lb-trans"><h3>美国十大高增长科技公司</h3>
</div><table>
<thead>
<tr>
<th>Name</th>
<th>Revenue Growth</th>
<th>Earnings Growth</th>
<th>Growth Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marker Therapeutics</td>
<td>61.33%</td>
<td>65.71%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Palantir Technologies</td>
<td>27.37%</td>
<td>30.93%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Reddit</td>
<td>21.66%</td>
<td>27.62%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Fabrinet</td>
<td>20.36%</td>
<td>22.11%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Sandisk</td>
<td>35.48%</td>
<td>49.66%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Tenaya Therapeutics</td>
<td>58.52%</td>
<td>60.10%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Zscaler</td>
<td>15.95%</td>
<td>49.84%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Circle Internet Group</td>
<td>20.27%</td>
<td>46.38%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Duos Technologies Group</td>
<td>36.60%</td>
<td>141.19%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>KVH Industries</td>
<td>25.44%</td>
<td>135.75%</td>
<td>★★★★★☆</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>名称</th>
<th>收入增长</th>
<th>盈利增长</th>
<th>增长评级</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marker Therapeutics</td>
<td>61.33%</td>
<td>65.71%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Palantir Technologies</td>
<td>27.37%</td>
<td>30.93%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Reddit</td>
<td>21.66%</td>
<td>27.62%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Fabrinet</td>
<td>20.36%</td>
<td>22.11%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Sandisk</td>
<td>35.48%</td>
<td>49.66%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Tenaya Therapeutics</td>
<td>58.52%</td>
<td>60.10%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Zscaler</td>
<td>15.95%</td>
<td>49.84%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Circle Internet Group</td>
<td>20.27%</td>
<td>46.38%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Duos Technologies Group</td>
<td>36.60%</td>
<td>141.19%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>KVH Industries</td>
<td>25.44%</td>
<td>135.75%</td>
<td>★★★★★☆</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 66 stocks from our US High Growth Tech and AI Stocks screener.</p>
<div class="lb-trans"><p>点击这里查看我们美国高增长科技和人工智能股票筛选器中的 66 只股票的完整列表。</p>
</div><p>Here's a peek at a few of the choices from the screener.</p>
<div class="lb-trans"><p>以下是筛选器中一些选择的预览。</p>
</div><h2>AvePoint (AVPT)</h2>
<div class="lb-trans"><h2>AvePoint (AVPT)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增长评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> AvePoint, Inc. offers a cloud-native data management software platform across various regions including North America, Europe, the Middle East, Africa, and the Asia Pacific with a market capitalization of approximately $2.16 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> AvePoint, Inc. 提供云原生数据管理软件平台，覆盖北美、欧洲、中东、非洲和亚太地区，市值约为 21.6 亿美元。</p>
</div><p><strong>Operations:</strong> The company generates revenue primarily from its software and programming segment, totaling $419.50 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司主要通过其软件和编程部门产生收入，总额为 4.195 亿美元。</p>
</div><p>AvePoint's recent trajectory illustrates a robust adaptation to the evolving tech landscape, underscored by a significant turnaround in financial performance. In 2025, the company reported a revenue increase to $419.5 million from $330.48 million the previous year, alongside an impressive swing to a net income of $34.8 million from a net loss of $29.09 million, reflecting an earnings growth of 32.07% per year. These figures are complemented by AvePoint's strategic enhancements in AI governance capabilities across multiple cloud platforms such as Microsoft 365 and Google Cloud, addressing critical multicloud compliance and data security challenges faced by enterprises today. This strategic pivot not only boosts their service offerings but also positions them well within the high-growth sectors of cloud governance and data management, tapping into escalating demands for integrated AI solutions that ensure both operational efficiency and stringent security protocols.</p>
<div class="lb-trans"><p>AvePoint 最近的轨迹展示了其对不断变化的科技环境的强大适应能力，财务表现显著好转。2025 年，该公司的收入从前一年的 3.3048 亿美元增加到 4.195 亿美元，同时净收入从 2909 万美元的净亏损转为 3480 万美元的净收入，反映出每年 32.07% 的盈利增长。这些数据得益于 AvePoint 在多个云平台（如 Microsoft 365 和 Google Cloud）上战略性增强的人工智能治理能力，解决了企业当前面临的关键多云合规和数据安全挑战。这一战略转变不仅提升了他们的服务产品，还使他们在云治理和数据管理的高增长领域中占据了良好位置，抓住了对集成 AI 解决方案日益增长的需求，这些解决方案确保了运营效率和严格的安全协议。</p>
</div><ul>
<li>Delve into the full analysis health report here for a deeper understanding of AvePoint.</li>
<li>Gain insights into AvePoint's past trends and performance with our Past report.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里深入了解 AvePoint 的完整分析健康报告。</li>
<li>通过我们的历史报告获取 AvePoint 的过去趋势和表现的见解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/757b1f34-6adb-40bf-9718-ec65d6ce15ee/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/757b1f34-6adb-40bf-9718-ec65d6ce15ee/chart/earnings-and-revenue-growth"/></p>
<p>AVPT Earnings and Revenue Growth as at Apr 2026</p>
<div class="lb-trans"><p>截至 2026 年 4 月的 AVPT 收益和收入增长</p>
</div><h2>Krystal Biotech (KRYS)</h2>
<div class="lb-trans"><h2>Krystal Biotech (KRYS)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增长评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Krystal Biotech, Inc. is a commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing genetic medicines for diseases with high unmet medical needs in the United States, with a market cap of $7.92 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Krystal Biotech, Inc. 是一家商业阶段的生物技术公司，专注于发现、开发、制造和商业化针对美国高未满足医疗需求疾病的基因药物，市值为 79.2 亿美元。</p>
</div><p><strong>Operations:</strong> Krystal Biotech generates revenue primarily from its genetic medicines segment, which amounted to $389.13 million. The company operates within the biotechnology sector, focusing on addressing diseases with significant unmet needs in the U.S.</p>
<div class="lb-trans"><p><strong>运营：</strong> Krystal Biotech 主要通过其基因药物部门产生收入，金额为 3.8913 亿美元。该公司在生物技术领域运营，专注于解决美国重大未满足需求的疾病。</p>
</div><p>Krystal Biotech stands out in the biotechnology landscape, showcasing a remarkable earnings growth of 129.7% over the past year, significantly outpacing the industry's average of 50.1%. This growth is underpinned by robust revenue and earnings forecasts, with expected annual increases of 19.8% and 22%, respectively, which eclipse broader market projections. The firm's commitment to innovation is evident in its recent FDA RMAT designation for KB707, aimed at treating advanced NSCLC—a testament to its potential in addressing critical unmet medical needs through advanced gene therapies. This strategic focus not only highlights Krystal’s role in pioneering new treatments but also positions it favorably within a competitive sector poised for rapid expansion.</p>
<div class="lb-trans"><p>Krystal Biotech 在生物技术领域脱颖而出，过去一年展现出 129.7% 的显著盈利增长，远超行业平均水平 50.1%。这一增长得益于强劲的收入和盈利预测，预计年增长分别为 19.8% 和 22%，超出更广泛市场的预期。该公司对创新的承诺在其最近获得 FDA RMAT 认证的 KB707 中得以体现，旨在治疗晚期非小细胞肺癌，这证明了其在通过先进基因疗法解决关键未满足医疗需求方面的潜力。这一战略重点不仅突显了 Krystal 在开创新疗法中的作用，还使其在一个快速扩张的竞争领域中占据了有利位置。</p>
</div><ul>
<li>Navigate through the intricacies of Krystal Biotech with our comprehensive health report here.</li>
<li>Review our historical performance report to gain insights into Krystal Biotech's's past performance.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里深入了解 Krystal Biotech 的复杂健康报告。</li>
<li>查看我们的历史表现报告，以获取 Krystal Biotech 过去表现的见解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0bee3c6e-0bb9-45f2-94da-e22eb8705c98/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/0bee3c6e-0bb9-45f2-94da-e22eb8705c98/chart/earnings-and-revenue-growth"/></p>
<p>KRYS Earnings and Revenue Growth as at Apr 2026</p>
<div class="lb-trans"><p>截至 2026 年 4 月的 KRYS 收益和收入增长</p>
</div><h2>Q2 Holdings (QTWO)</h2>
<div class="lb-trans"><h2>Q2 Holdings (QTWO)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增长评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Q2 Holdings, Inc. offers digital solutions tailored for financial institutions, FinTechs, and alternative finance companies across the United States, with a market capitalization of $3.03 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Q2 Holdings, Inc. 提供针对金融机构、金融科技公司和替代金融公司的数字解决方案，市值为 30.3 亿美元。</p>
</div><p><strong>Operations:</strong> Q2 Holdings generates revenue primarily through the sale, implementation, and support of its digital solutions, amounting to $794.81 million. The company caters to financial institutions and FinTechs in the U.S., focusing on providing technology-driven services.</p>
<div class="lb-trans"><p><strong>运营：</strong> Q2 Holdings 主要通过销售、实施和支持其数字解决方案产生收入，总额为 7.9481 亿美元。该公司为美国的金融机构和金融科技公司提供技术驱动的服务。</p>
</div><p>Q2 Holdings is distinguishing itself in the tech sector with a strong focus on AI-driven solutions for financial services, evidenced by its recent unveiling of User Activity Monitoring and Restricted Entitlements Mode to enhance fraud protection. These innovations are part of Q2's broader strategy to integrate AI seamlessly within digital banking operations, reflecting a significant shift towards more dynamic, real-time fraud mitigation techniques. Financially, Q2 has demonstrated robust growth with a 34.5% annual increase in earnings and an impressive 9.6% rise in revenue year-over-year. This performance is underpinned by strategic initiatives like Second Quarter Code, which accelerates development cycles within financial institutions by leveraging generative AI, thereby enhancing the platform's utility and attractiveness in a competitive market.</p>
<div class="lb-trans"><p>Q2 Holdings 在科技行业中脱颖而出，专注于为金融服务提供基于人工智能的解决方案，最近推出的用户活动监控和限制权限模式便是其增强防欺诈保护的有力证明。这些创新是 Q2 更广泛战略的一部分，旨在将人工智能无缝整合到数字银行业务中，反映出向更动态、实时的欺诈缓解技术的显著转变。在财务方面，Q2 展现出强劲的增长，年收益增长 34.5%，年收入增长 9.6%。这一表现得益于诸如第二季度代码等战略举措，该举措通过利用生成性人工智能加速金融机构的开发周期，从而提升平台在竞争市场中的实用性和吸引力。</p>
</div><ul>
<li>Dive into the specifics of Q2 Holdings here with our thorough health report.</li>
<li>Assess Q2 Holdings' past performance with our detailed historical performance reports.</li>
</ul>
<div class="lb-trans"><ul>
<li>在这里深入了解 Q2 Holdings 的详细健康报告。</li>
<li>通过我们的详细历史业绩报告评估 Q2 Holdings 的过去表现。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/7cb340fc-3efd-4236-8da6-fed86e0ccf86/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/7cb340fc-3efd-4236-8da6-fed86e0ccf86/chart/earnings-and-revenue-growth"/></p>
<p>QTWO Earnings and Revenue Growth as at Apr 2026</p>
<div class="lb-trans"><p>截至 2026 年 4 月的 QTWO 收益和收入增长</p>
</div><h2>Make It Happen</h2>
<div class="lb-trans"><h2>让它发生</h2>
</div><ul>
<li>Investigate our full lineup of 66 US High Growth Tech and AI Stocks right here.</li>
<li>Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.</li>
<li>Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.</li>
</ul>
<div class="lb-trans"><ul>
<li>在这里探索我们完整的 66 家美国高增长科技和人工智能股票阵容。</li>
<li>投资了这些股票吗？通过 Simply Wall St 简化您的投资组合管理，并通过我们的警报及时获取股票的关键更新。</li>
<li>通过 Simply Wall St 的免费应用程序发现投资机会的世界，获取各市场无与伦比的股票分析。</li>
</ul>
</div><h2>Ready To Venture Into Other Investment Styles?</h2>
<div class="lb-trans"><h2>准备探索其他投资风格吗？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
<li>Find companies with promising cash flow potential yet trading below their fair value.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>用显示强劲增长潜力的公司充实您的投资组合，分析师和管理层均持乐观态度。</li>
<li>寻找现金流潜力良好但交易价格低于其公允价值的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>本文由 Simply Wall St 撰写，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，采用无偏见的方法，我们的文章并不构成财务建议。</strong> 这并不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们旨在为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均没有持仓。</em></p>
</div><h3>Valuation is complex, but we're here to simplify it.</h3>
<div class="lb-trans"><h3>估值复杂，但我们在这里为您简化。</h3>
</div><p>Discover if Q2 Holdings might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p>
<div class="lb-trans"><p>通过我们的详细分析，发现 Q2 Holdings 是否可能被低估或高估，分析内容包括 <strong>公允价值估算、潜在风险、股息、内部交易和财务状况。</strong></p>
</div><p>Access Free Analysis</p>
<div class="lb-trans"><p>获取免费分析</p>
</div>

High Growth Tech Stocks To Watch In The US April 2026

- 美国市场过去一周保持平稳，年增幅达 29%。  
- 高增长科技公司依靠创新和适应力抓住市场机遇。  
- 文章列出多家强劲成长的科技公司及其财务表现。

2026 年 4 月美国值得关注的高增长科技股票